Recent update on application of dihydromyricetin in metabolic related diseases

• Published in: Biomedicine & pharmacotherapy 2022-04, Vol.148, p.112771-112771, Article 112771
• Main Authors: Wang, Yirong, Wang, Junmin, Xiang, Hongjiao, Ding, Peilun, Wu, Tao, Ji, Guang
• Format: Article
• Language: English
• Subjects: AMP-Activated Protein Kinases - drug effects; Anti-Inflammatory Agents - pharmacology; Antioxidants - pharmacology; Cancers; Cell Death; Dihydromyricetin; Flavonols - pharmacology; Glucose - metabolism; Humans; Lipid Metabolism - drug effects; Liver diseases; Liver Diseases - pathology; Metabolic diseases; Metabolic Diseases - pathology; MicroRNAs - metabolism; Neoplasms - pathology; Oxidative Stress - drug effects; Peroxisome Proliferator-Activated Receptors - drug effects; Phosphatidylinositol 3-Kinases - drug effects; Proto-Oncogene Proteins c-akt - drug effects; Signal Transduction - drug effects
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2022.112771

As a new type of natural flavonoids, dihydromyricetin (DMY) has attracted more and more attention. It has a series of pharmacological effects, such as anti-inflammatory, anti-tumor, anti-oxidation, antibacterial and so on, and it is almost no toxicity and with excellent safety. Therefore, even if the bioavailability is poor, it is often added to daily food, beverages and even medicines. In recent years, some researchers have found that DMY can treat some diseases by anti-oxidation, anti-inflammation, promoting cell death and regulate the activity of lipid and glucose metabolism. In addition, the mechanism of DMY on these diseases was also related to the signal pathway of AMPK, PI3K/Akt, PPAR and the participation of microRNAs. This review describes the mechanism of DMY in metabolic related diseases from three aspects: metabolic diseases, liver diseases, and cancers, hoping to provide some new ideas for clinical researches. [Display omitted] The mechanism of DMY with some associated metabolic diseases. Abbreviations DMY, dihydromyricetin; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol-3-kinase; mTOR, Mechanistic target of rapamycin; AMPK, adenosine monophosphate activated protein kinase; NF-κB, nuclear factor kappa-B; TGF-β, transforming growth factor-β; Bcl-2, B-cell lymphoma-2; ERK1/2, extracellular signal-regulated kinase 1/2. •DMY has anti-inflammatory, anti-tumor, antioxidant, antibacterial and other pharmacological effects.•DMY can protect liver and alleviate metabolic syndrome.•DMY may be a potential natural drug for the treatment of cancers.